Changes

*Met w/ Norm about depression research (Brian Mickey and Grace Lee) and promotion requirements (Harriet Hopf). Ketamine may have an active metabolite that sticks around, explaining its long lasting effects (Nature paper).

*Met w/ Norm about depression research (Brian Mickey and Grace Lee) and promotion requirements (Harriet Hopf). Ketamine may have an active metabolite that sticks around, explaining its long lasting effects (Nature paper).

*Lit review of Yohimbine and Naloxone effects on EEG.

*Lit review of Yohimbine and Naloxone effects on EEG.

*Dug through supplement of 2026 A&A paper to find which anesthetics are most selective for which receptors.

*Dug through supplement of 2026 A&A paper to find which anesthetics are most selective for which receptors ''in vitro''.

*Thought about Jellyfish, Corral, Hydra

*Thought about Jellyfish, Corral, Hydra

*[https://pmc.ncbi.nlm.nih.gov/articles/PMC12998346/ Remimazolam targets]: the theoretical initial target concentration of remimazolam may be 0.1 µg/mL for light sedation, 0.2 µg/mL for moderate sedation, and 0.3 µg/mL for deep sedation in elderly patients (70 years), and 1.5 or 2 times those concentrations in middle-aged (45 years) or young adult (20 years) patients. Dose adjust upwards by 10% in females, down by 20% in obesity or ASA III/IV.

*[https://pmc.ncbi.nlm.nih.gov/articles/PMC12998346/ Remimazolam targets]: the theoretical initial target concentration of remimazolam may be 0.1 µg/mL for light sedation, 0.2 µg/mL for moderate sedation, and 0.3 µg/mL for deep sedation in elderly patients (70 years), and 1.5 or 2 times those concentrations in middle-aged (45 years) or young adult (20 years) patients. Dose adjust upwards by 10% in females, down by 20% in obesity or ASA III/IV.